NEJM Interviews

NEJM Interview: Peter Ubel on strategies for protecting patients from high out-of-pocket costs for drugs with questionable benefits. Feb 19, 2025

Peter Ubel is a professor of business, public policy, and medicine at Duke University. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. P.A. Ubel, A. Grouls, and A.S. Kesselheim. Out of Pocket Getting Out of Hand — Reducing the Financial Toxicity of Rapidly Approved Drugs. N Engl J Med 2025;392:729-731.

NEJM Interview: Yashaswini Singh on the expansion of private equity investments in health care and actions to safeguard patient interests in various countries. Feb 12, 2025

Yashaswini Singh is an assistant professor of health services, policy, and practice at Brown University. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. Y. Singh, E. Fuse Brown, and I. Papanicolas. The Rise of Private Equity in Health Care — Not a Uniquely American Phenomenon. N Engl J Med 2025;392:627-629.

NEJM Interview: Joseph Ross on the newly implemented Cell and Gene Therapy Access Model. Feb 05, 2025

Joseph Ross is a professor in the Department of Internal Medicine at the Yale School of Medicine and in the Department of Health Policy and Management at the Yale School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.S. Ross. Cell and Gene Therapies — Improving Access and Outcomes for Medicare and Medicaid Beneficiaries. N Engl J Med 2025;392:521-523.

NEJM Interview: Daniel Aaron on a Supreme Court case about e-cigarettes that could have implications for the FDA’s authority and for public health. Jan 29, 2025

Daniel Aaron is an associate professor of law at the University of Utah S.J. Quinney College of Law. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.G. Aaron and C. Robertson. E-Cigarettes at the Supreme Court — Potential Implications for the FDA and Public Health. N Engl J Med 2025;392:417-419.

NEJM Interview: Craig Spencer on the need for action to address persistent inequities in global health. Jan 22, 2025

Craig Spencer is an emergency medicine physician and an associate professor of the practice of health services, policy, and practice at the Brown University School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. C. Spencer. Ebola and a Decade of Disparities — Forging a Future for Global Health Equity. N Engl J Med 2025;392:313-315.

NEJM Interview: Carmel Shachar on modernizing labor laws and strike regulations to support physicians, patients, and hospitals. Jan 15, 2025

Carmel Shachar is an assistant clinical professor of law and faculty director of the Health Law and Policy Clinic at Harvard Law School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. T. Ramesh, C. Shachar, and H. Yu. Striking a Balance — Advancing Physician Collective-Bargaining Rights and Patient Protections. N Engl J Med 2025;392:209-211.

NEJM Interview: David Velasquez on care for older, low-income adults who can’t enroll in Medicare or Medicaid because they’re undocumented immigrants. Jan 08, 2025

David Velasquez is an internal medicine resident physician at Brigham and Women's Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.E. Velasquez, E.T. Roberts, and J.F. Figueroa. The Plight of “Dual Noneligible” People in the United States. N Engl J Med 2025;392:105-107.

NEJM Interview: Joey Mattingly on providing widespread access to HCV treatment at the lowest possible price. Jan 01, 2025

Joey Mattingly is an associate professor in the Department of Pharmacotherapy at the University of Utah College of Pharmacy. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. S.S. Tu, S. Kottilil, and T.J. Mattingly II. Leveraging Old Hepatitis C Therapies. N Engl J Med 2025;392:1-4.

NEJM Interview: Lauren Schiff on the need for improved training and increased comfort in treating autistic people. Dec 18, 2024

Lauren Schiff is an associate professor of Ob/Gyn and a minimally invasive gynecologic surgeon at the University of North Carolina School of Medicine and the associate chief medical officer for quality and safety at UNC Hospitals. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.D. Schiff, A.O.D. Hester, and T. Benevides. Providing Effective Medical Care to Autistic People. N Engl J Med 2024;391:2281-2283.

NEJM Interview: Bindu Kanapuru on the FDA’s new expedited withdrawal procedure for accelerated approvals. Dec 11, 2024

Bindu Kanapuru is a hematologist–oncologist physician in the Office of Oncologic Diseases at the FDA’s Center for Drug Evaluation and Research. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. B. Kanapuru and Others. Autopsy of a Drug Withdrawal — The Case of Melphalan Flufenamide. N Engl J Med 2024;391:2177-2179.

NEJM Interview: Karen Joynt Maddox on the Transforming Episode Accountability Model recently announced by CMS. Dec 04, 2024

Karen Joynt Maddox is an associate professor of medicine at Washington University School of Medicine. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. S.A. Shashikumar, A.M. Ryan, and K.E. Joynt Maddox. Medicare’s New Mandatory Bundled-Payment Program — Are We Ready for TEAM? N Engl J Med 2024;391:2065-2067.

NEJM Interview: Andrew Hantel on a source of discrimination against some patients in cancer research and care practices. Nov 27, 2024

Andrew Hantel is an assistant professor of medicine at Harvard Medical School and a faculty member in the Divisions of Leukemia and Population Sciences at Dana-Farber Cancer Institute and at the HMS Center for Bioethics. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A. Hantel and Others. The Duffy Null Phenotype — Addressing a Source of Discrimination in Cancer Care. N Engl J Med 2024;391:1969-1972.

NEJM Interview: Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act. Nov 20, 2024

Benjamin Rome is a physician and health policy researcher at Brigham and Women’s Hospital and an assistant professor of medicine at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. B.N. Rome, A.S. Kesselheim, and W.B. Feldman. Medicare’s First Round of Drug-Price Negotiation — Measuring Success. N Engl J Med 2024;391:1865-1868.

NEJM at AHA — Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease Nov 17, 2024

Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N Engl J Med. DOI: 10.1056/NEJMe2414477.

NEJM at AHA — Routine Spironolactone in Acute Myocardial Infarction Nov 16, 2024

Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Routine Spironolactone in Acute Myocardial Infarction. N Engl J Med. DOI: 10.1056/NEJMe2414472.

NEJM at AHA — Left Atrial Appendage Closure after Ablation for Atrial Fibrillation Nov 15, 2024

Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. N Engl J Med. DOI: 10.1056/NEJMe2414475.

NEJM at AHA — Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia Nov 15, 2024

Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. N Engl J Med. DOI: 10.1056/NEJMe2414471.

NEJM at AHA — CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy Nov 15, 2024

Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMe2414473.

NEJM at AHA — Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Nov 15, 2024

Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. DOI: 10.1056/NEJMe2414470.

NEJM at AHA — Intensive Blood-Pressure Control in Patients with Type 2 Diabetes Nov 15, 2024

Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. DOI: 10.1056/NEJMe2414476.

NEJM Interview: Heather Hsu on an institutional conference series that provides opportunities for addressing the adverse effects of bias and medical racism. Nov 13, 2024

Heather Hsu is a pediatric hospitalist at Boston Medical Center and an assistant professor of pediatrics at the Boston University Chobanian and Avedisian School of Medicine. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. K.A. Nash, J. Perdomo, and H.E. Hsu. Health Equity Rounds — Root-Cause and Solutions-Oriented Discussions of Medical Racism. N Engl J Med 2024;391:1763-1765.

The Marburg Virus Outbreak in Rwanda Nov 06, 2024

Eric Rubin is the Editor-in-Chief of the Journal. Lindsey Baden is a Deputy Editor of the Journal. Sabin Nsanzimana, M.D., Ph.D., is the Minister of Health of Rwanda. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin and Others. Audio Interview: The Marburg Virus Outbreak in Rwanda. N Engl J Med 2024;391:e49.

NEJM Interview: Vincent Guilamo-Ramos on the need to rethink the response to HIV in Latino communities. Nov 06, 2024

Vincent Guilamo-Ramos is the executive director of the Institute for Policy Solutions at the Johns Hopkins School of Nursing. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. V. Guilamo-Ramos, M. Thimm-Kaiser, and A. Benzekri. The U.S. Latino HIV Crisis — Ending an Era of Invisibility. N Engl J Med 2024;391:1665-1668.

NEJM Interview: Liam McCoy on concerns about the implementation of large language models in note writing and related clinical tasks. Oct 30, 2024

Liam McCoy is a resident physician in neurology at the University of Alberta. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.G. McCoy, A.K. Manrai, and A. Rodman. Large Language Models and the Degradation of the Medical Record. N Engl J Med 2024;391:1561-1564.

NEJM Interview: Mark Wicclair on approaches to protecting both physicians’ conscience and patients’ health. Oct 23, 2024

Mark Wicclair is an adjunct professor of medicine at the University of Pittsburgh Center for Bioethics and Health Law and a professor of philosophy emeritus at West Virginia University. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.B. White and M. Wicclair. Navigating Clinicians’ Conscience-Based Refusals to Provide Lawful Medical Care. N Engl J Med 2024;391:1465-1467.

NEJM Interview: Jose Figueroa on the potential effects of the results of the 2024 elections on health care access, affordability, and equity. Oct 16, 2024

Jose Figueroa is an associate professor of health policy and management at the Harvard T.H. Chan School of Public Health and an assistant professor of medicine at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.M. McWilliams and S.B. Dusetzina. Affordability of Health Care in the United States — Old Problems Awaiting a New Administration. N Engl J Med 2024;391:1372-1374. M. Alsan and R. Yearby. Health Equity in the 2024 U.S. Presidential Election. N Engl J Med 2024;391:1374-1377. S. Glied and B.D. Sommers. Health Coverage, Access, and the 2024 U.S. Elections. N Engl J Med 2024;391:1369-1372.

NEJM Interview: Jean Nachega on the mpox Public Health Emergency of International Concern. Oct 09, 2024

Jean Nachega is an associate professor of infectious diseases and microbiology and of epidemiology at the University of Pittsburgh School of Public Health and a professor of medicine at Stellenbosch University. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.B. Nachega and Others. Mpox in Pregnancy — Risks, Vertical Transmission, Prevention, and Treatment. N Engl J Med 2024;391:1267-1270.

NEJM Interview: Jonathan Oberlander on the implications of the 2024 U.S. elections for health care reform. Oct 02, 2024

Jonathan Oberlander is a professor of social medicine and of health policy and management at the University of North Carolina at Chapel Hill. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J. Oberlander. Health Care Reform and the 2024 U.S. Elections — Low Visibility, High Stakes. N Engl J Med 2024;391:1169-1171.

NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma Sep 15, 2024

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors Sep 15, 2024

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESMO — Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer Sep 14, 2024

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESMO — Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer Sep 14, 2024

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma Sep 14, 2024

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer Sep 14, 2024

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma Sep 14, 2024

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESMO — Ponsegromab in Cancer Cachexia Sep 13, 2024

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESMO — Pembrolizumab in HER2+ Gastric Cancer Sep 13, 2024

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESMO — Preoperative Chemoradiotherapy for Resectable Gastric Cancer Sep 13, 2024

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESC — Finerenone in Heart Failure for Mildly Reduced or Preserved Ejection Fraction Aug 31, 2024

Did you miss the ESC Congress 2024? In this podcast, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Have a listen! Visit NEJM.org to read the latest research.

NEJM at ESC — Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk Sep 01, 2024

Did you miss the ESC Congress 2024? In a series of audio interviews (featured below), Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.

NEJM at ESC — Invasive versus Conservative Strategy for Older Patients with Myocardial Infarction Aug 31, 2024